Company intelligence / Profile preview

Logical Antigen

Sandwich, Kent, United Kingdom

Ownership: Private
Development stage: Other

Overview

Logical Antigen is newly established (2025), specializing in rapid, customized, high-quality native and recombinant antigen and biological production for the research and diagnostic (mainly IVD) market. Their state-of-the-art processes enable delivery of custom materials in weeks rather than years. Clinical results per se do not apply; company impact centers on enabling and accelerating diagnostic development timelines for industry partners and diagnostic product manufacturers.

Therapeutic areas: Infectious Diseases
Modalities: ProteinRecombinant proteinBiologic
Industry: Chemicals & Materials

Partnerships

Logical Biological (shared business/commercial infrastructure and product integration)Bcell Design (strategic partnership for engineered disease state materials, shared supply and custom product development)

Beyond the preview

Go deeper on Logical Antigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Logical Antigen.

Explore the full profile